Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02478268 · ClinicalTrials.gov registry record · Phase 1
Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
A Phase 1 study, sponsored by Bastiaan Driehuys.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02478268 is a Phase 1 study that has completed, run by Bastiaan Driehuys. The registered enrollment target is 64 participants.
The verdict
NCT02478268, a Phase 1 study, has completed, sponsored by Bastiaan Driehuys.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung function and detect changes over time in patients receiving treatment as well as those who don't. 129Xe is a special type of xenon gas and when inhaled during MRI may be able to show areas of abnormal thickening of parts of the lungs. These images combined with images taken with injected contrast agents or other types of MRI may provide a better way to look at lung structure and function in patients with IPF. The ultimate goal is to predict how a particular patient might respond to a particular therapy and to observe such responses earlier than conventional tests. The investigators anticipate that the images acquired in this study will provide more specific information about lung disease than standard lung function tests. The use of 129Xe MRI is investigational. "Investigational" means that these tests have not yet been approved by the US Food and Drug Administration and are being tested in research studies like this one. In addition, standard MRI with contrast is not typically done as standard of care for monitoring progression of IPF, therefore, its use in this study is also considered investigational. Healthy volunteers are being asked to participate in this study because the investigators need to develop a database of functional images that are representative of healthy lungs.
Interventions
- DEVICE MRI
- DRUG Hyperpolarized 129-Xenon gas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-05 |
| Est. Completion | 2020-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02478268
The ClinicalTrials.gov registry entry for NCT02478268 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI is the first listed.
NCT02478268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02478268 about?
NCT02478268 is a clinical study titled "Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis". The purpose of this study is to determine whether magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung function and detect changes over time in patients receiving treatment as well as those who don't. 129Xe is a special t...
What is the current status of trial NCT02478268?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2015-05. Estimated completion is 2020-09-26.
What interventions are being tested in trial NCT02478268?
The interventions under investigation include: MRI (DEVICE), Hyperpolarized 129-Xenon gas (DRUG).
Who is sponsoring clinical trial NCT02478268?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.